MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB–IIIB NSCLC
Clinical Lung Cancer · 2024-09 · 25 (6) · 587-593.e3
DOI: 10.1016/j.cllc.2024.06.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lung Cancer, 2024-09. Verfasst von Martin Reck und 11 weiteren Autor:innen. Beteiligte Einrichtung: Lung Clinic Großhansdorf, Airway Research Center North, German Center for Lung Research, Großhansdorf, Germany. Electronic address: m.reck@lungenclin…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Chemoradiotherapy. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca PLC.
Themen: Onkologische Pflege
Abstract (Originalsprache)
INTRODUCTION: In the AEGEAN trial, neoadjuvant durvalumab plus platinum-based chemotherapy (D+CT) followed by adjuvant durvalumab, versus neoadjuvant chemotherapy alone, significantly improved pathological complete response (pCR) rate and event-free survival (EFS) in patients with resectable NSCLC. In the PACIFIC trial, consolidation durvalumab significantly improved progression-free (PFS) and overall survival (OS) for patients with unresectable stage III NSCLC after chemoradiotherapy. Strong pathological and clinical outcomes with chemoimmunotherapy have generated interest in its use to enable patients with borderline-resectable NSCLC to undergo surgery. Additionally, for patients initially deemed resectable but who later become unresectable/inoperable during neoadjuvant treatment, consolidation immunotherapy after chemoradiotherapy should be explored. PATIENTS AND METHODS: MDT-BRIDGE (NCT05925530) is a multicenter, phase II, non-randomized study in ∼140 patients with EGFR/ALK wild-type, stage IIB-IIIB (N2) NSCLC. Following baseline multidisciplinary team (MDT) assessment to determine resectable/borderline-resectable status, all patients receive 2 cycles of neoadjuvant D+CT every 3 weeks, followed by MDT reassessment of resectability. Patients deemed resectable receive 1-2 additional cycles of D+CT followed by surgery (Cohort 1). Patients deemed unresectable receive standard-of-care chemoradiotherapy (Cohort 2). Cohort 1 patients who become ineligible for surgery can enter Cohort 2. Following surgery or chemoradiotherapy, patients receive adjuvant or consolidation durvalumab for 1 year. The primary endpoint is resection rate in all patients. Additional endpoints include resection rates by baseline resectable/borderline-resectable status, resection outcomes, EFS/PFS, OS, pCR rate, circulating tumor DNA dynamics pre- and post-surgery (including correlation with clinical outcomes), and safety. CONCLUSION: Enrollment began in February 2024; primary completion is anticipated in April 2026.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lung Clinic Großhansdorf, Airway Research Center North, German Center for Lung Research, Großhansdorf, Germany. Electronic address: m.reck@lungenclinic.de.
- Medical Oncology Department, Institut Català d'Oncologia - ICO Hospitalet, Barcelona, Spain.
- Institut du Thorax Curie Montsouris, Institut Curie, Paris, France, and UVSQ, Paris Saclay, Versailles, France.
- Department of Oncology and Hemato-Oncology, University of Milan, and Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Department of Surgery, Division of Thoracic Surgery, University of Virginia, Charlottesville, VA.
- University of Texas MD Anderson Cancer Center, Houston, TX.
Förderung
- AstraZeneca PLC
Zitieren
APA
Reck, M., Nadal, E., Girard, N., Filippi, A. R., Martin, L. W., Gay, C. M., Petersen, C., Gale, D., Emeribe, U. A., Georgoulia, N., Perez, I. E. D., & Spicer, J. D. (2024). MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB–IIIB NSCLC. Clinical Lung Cancer, 25(6), 587-593.e3. https://doi.org/10.1016/j.cllc.2024.06.007
Vancouver
Reck M, Nadal E, Girard N, Filippi AR, Martin LW, Gay CM, et al. MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB–IIIB NSCLC. Clinical Lung Cancer. 2024;25(6):587-593.e3. doi:10.1016/j.cllc.2024.06.007
BibTeX
@article{Reck2024,
author = {Reck, Martin and Nadal, Ernest and Girard, Nicolas and Filippi, Andrea R and Martin, Linda W and Gay, Carl M and Petersen, Cordula and Gale, Davina and Emeribe, Ugochinyere A and Georgoulia, Nefeli and Perez, Ignacio E Diaz and Spicer, Jonathan D},
title = {MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB–IIIB NSCLC},
journal = {Clinical Lung Cancer},
year = {2024},
volume = {25},
number = {6},
pages = {587--593.e3},
doi = {10.1016/j.cllc.2024.06.007}
}
EUVIMED